Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia.
atherosclerosis
hyperlipidemias
inflammation
lymph nodes
xanthomatosis
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
20
5
2022
medline:
25
6
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
HDL (high-density lipoprotein) and its major protein component, apoA-I (apolipoprotein A-I), play a unique role in cholesterol homeostasis and immunity. ApoA-I deficiency in hyperlipidemic, atheroprone mice was shown to drive cholesterol accumulation and inflammatory cell activation/proliferation. The present study was aimed at investigating the impact of apoA-I deficiency on lipid deposition and local/systemic inflammation in normolipidemic conditions. ApoE deficient mice, apoE/apoA-I double deficient (DKO) mice, DKO mice overexpressing human apoA-I, and C57Bl/6J control mice were fed normal laboratory diet until 30 weeks of age. Plasma lipids were quantified, atherosclerosis development at the aortic sinus and coronary arteries was measured, skin ultrastructure was evaluated by electron microscopy. Blood and lymphoid organs were characterized through histological, immunocytofluorimetric, and whole transcriptome analyses. DKO were characterized by almost complete HDL deficiency and by plasma total cholesterol levels comparable to control mice. Only DKO showed xanthoma formation and severe inflammation in the skin-draining lymph nodes, whose transcriptome analysis revealed a dramatic impairment in energy metabolism and fatty acid oxidation pathways. An increased presence of CD4 HDL deficiency, in the absence of hyperlipidemia, is associated with severe alterations of skin morphology, aortic and coronary atherosclerosis, local and systemic inflammation.
Sections du résumé
BACKGROUND
HDL (high-density lipoprotein) and its major protein component, apoA-I (apolipoprotein A-I), play a unique role in cholesterol homeostasis and immunity. ApoA-I deficiency in hyperlipidemic, atheroprone mice was shown to drive cholesterol accumulation and inflammatory cell activation/proliferation. The present study was aimed at investigating the impact of apoA-I deficiency on lipid deposition and local/systemic inflammation in normolipidemic conditions.
METHODS
ApoE deficient mice, apoE/apoA-I double deficient (DKO) mice, DKO mice overexpressing human apoA-I, and C57Bl/6J control mice were fed normal laboratory diet until 30 weeks of age. Plasma lipids were quantified, atherosclerosis development at the aortic sinus and coronary arteries was measured, skin ultrastructure was evaluated by electron microscopy. Blood and lymphoid organs were characterized through histological, immunocytofluorimetric, and whole transcriptome analyses.
RESULTS
DKO were characterized by almost complete HDL deficiency and by plasma total cholesterol levels comparable to control mice. Only DKO showed xanthoma formation and severe inflammation in the skin-draining lymph nodes, whose transcriptome analysis revealed a dramatic impairment in energy metabolism and fatty acid oxidation pathways. An increased presence of CD4
CONCLUSIONS
HDL deficiency, in the absence of hyperlipidemia, is associated with severe alterations of skin morphology, aortic and coronary atherosclerosis, local and systemic inflammation.
Identifiants
pubmed: 35587694
doi: 10.1161/ATVBAHA.122.317790
pmc: PMC9205301
doi:
Substances chimiques
Apolipoprotein A-I
0
Apolipoproteins E
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-856Références
N Engl J Med. 2007 Nov 22;357(21):2109-22
pubmed: 17984165
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):651-667
pubmed: 33327742
Trends Pharmacol Sci. 2019 Feb;40(2):104-115
pubmed: 30665623
J Lipid Res. 1989 Dec;30(12):1997-2004
pubmed: 2516111
Circ Res. 2002 Feb 22;90(3):270-6
pubmed: 11861414
Arterioscler Thromb. 1994 Jan;14(1):133-40
pubmed: 8274468
Handb Exp Pharmacol. 2015;224:483-508
pubmed: 25522999
Cardiovasc Res. 2014 Aug 1;103(3):362-71
pubmed: 24891399
J Clin Invest. 1999 Jul;104(1):31-9
pubmed: 10393696
Circ Res. 2016 Feb 19;118(4):679-91
pubmed: 26892966
Inflamm Res. 2006 Aug;55(8):322-34
pubmed: 16977379
Sci Rep. 2021 Dec 6;11(1):23458
pubmed: 34873191
Br J Pharmacol. 2020 Jan;177(2):328-345
pubmed: 31621898
J Lipid Res. 2018 Dec;59(12):2421-2435
pubmed: 30333156
Nat Immunol. 2021 Oct;22(10):1210-1217
pubmed: 34545250
Cardiovasc Res. 2019 Jul 1;115(9):1393-1407
pubmed: 31095280
Cell. 1992 Oct 16;71(2):343-53
pubmed: 1423598
Br J Pharmacol. 2011 Nov;164(5):1460-8
pubmed: 21486287
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1050-9
pubmed: 18323516
Eur Heart J. 2017 Aug 21;38(32):2478-2486
pubmed: 28419274
BMJ. 2014 Jul 18;349:g4379
pubmed: 25038074
Eur Heart J. 2015 Mar 1;36(9):539-50
pubmed: 24474739
J Clin Endocrinol Metab. 2012 Feb;97(2):E248-56
pubmed: 22090275
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):e131-e157
pubmed: 28729366
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1589-94
pubmed: 12829524
Cardiovasc Res. 2014 Aug 1;103(3):395-404
pubmed: 24891400
J Biol Chem. 2010 Nov 12;285(46):36158-69
pubmed: 20833724
Cardiovasc Res. 2021 Jul 27;117(9):2069-2082
pubmed: 32931583
Toxicol Lett. 2009 Oct 28;190(2):231-7
pubmed: 19647056
J Clin Invest. 1993 Nov;92(5):2262-73
pubmed: 7693760
Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):267-278
pubmed: 31694394
J Am Heart Assoc. 2016 Nov 7;5(11):
pubmed: 27821400
Sci Adv. 2020 Dec 11;6(50):
pubmed: 33310846
Atherosclerosis. 2006 Dec;189(2):255-63
pubmed: 16423356
J Lipid Res. 2015 Mar;56(3):635-643
pubmed: 25593328
Cells. 2021 Apr 29;10(5):
pubmed: 33947039
Cell Metab. 2017 Jun 6;25(6):1294-1304.e6
pubmed: 28479366
Can J Cardiol. 2019 Oct;35(10):1400-1408
pubmed: 31495683
Front Pharmacol. 2015 Oct 16;6:222
pubmed: 26528181
Immunity. 2016 Dec 20;45(6):1311-1326
pubmed: 28002731
Nat Commun. 2018 Aug 6;9(1):3083
pubmed: 30082772
Mol Nutr Food Res. 2020 Aug;64(15):e1900835
pubmed: 32579743
PLoS One. 2009 Dec 01;4(12):e8103
pubmed: 19956623
Vascul Pharmacol. 2015 Nov;74:114-121
pubmed: 26254103
Curr Opin Lipidol. 2010 Aug;21(4):289-97
pubmed: 20616715
Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):434-8
pubmed: 1703299
Liver Int. 2012 Oct;32(9):1363-71
pubmed: 22845860
J Clin Invest. 1994 Aug;94(2):899-903
pubmed: 8040345
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9607-11
pubmed: 7937814
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Am J Pathol. 2003 Sep;163(3):1201-13
pubmed: 12937162
J Mol Cell Cardiol. 2019 Feb;127:270-276
pubmed: 30639412
Clin Chem. 2019 May;65(5):644-652
pubmed: 30745290
Mol Imaging. 2014;13:
pubmed: 24825406
Methods Enzymol. 1986;128:553-82
pubmed: 3724523
Sci Rep. 2017 Mar 14;7:44503
pubmed: 28291223
Front Immunol. 2018 Feb 19;9:270
pubmed: 29520272
Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):843-9
pubmed: 19286630
J Immunol. 2015 Nov 15;195(10):4685-98
pubmed: 26466956
Pharmacol Res. 2019 Mar;141:189-200
pubmed: 30593851
Curr Opin Lipidol. 2019 Dec;30(6):462-469
pubmed: 31577612
Circ Res. 2019 May 10;124(10):1505-1518
pubmed: 31071007
Exp Cell Res. 2015 Oct 15;338(1):105-12
pubmed: 26241937
J Clin Lipidol. 2013 Sep-Oct;7(5):484-525
pubmed: 24079290